Skip to main content
AVBP
NASDAQ Life Sciences

ArriVent Secures IND Clearance for Novel Cancer Drug ARR-002, Advancing to Phase 1 Trials

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$29.62
Mkt Cap
$1.373B
52W Low
$16.1
52W High
$32.14
52W Position info
84% above low
Off High info
7.8% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

AVBP sits 84% above its 52-week low of $16.1.

Summary

ArriVent BioPharma has announced Investigational New Drug (IND) clearance for its novel tetravalent MUC16/NaPi2b targeting antibody-drug conjugate (ADC), ARR-002. This clearance allows the company to initiate human clinical trials for the drug, with an initial focus on ovarian and endometrial cancers. The company anticipates beginning Phase 1 trials in the second half of 2026. This is a significant positive development for ArriVent, as IND clearance is a critical de-risking event that enables the progression of a key pipeline candidate into human studies. Traders will now monitor for the commencement of the Phase 1 trial and future updates on its progress.

At the time of this announcement, AVBP was trading at $29.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $16.10 to $32.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

AVBP - Latest Insights

AVBP
Nov 09, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $13.75 info
Change: -$0.410 (-3%) info
Market Cap: $698.52M info
AVBP
Nov 09, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $13.75 info
Change: -$0.410 (-3%) info
Market Cap: $698.52M info
AVBP
Nov 09, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $13.75 info
Change: -$0.410 (-3%) info
Market Cap: $698.52M info
AVBP
Oct 26, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.30
Real-time Price: $13.75 info
Change: -$9.55 (-41%) info
Market Cap: $698.52M info
AVBP
Oct 12, 2026, 5:29 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $16.46
Real-time Price: $13.75 info
Change: -$2.71 (-16%) info
Market Cap: $698.52M info